Brii Biosciences (HKSE:02137) Debt-to-Equity : 0.00 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Brii Biosciences Debt-to-Equity?

Brii Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$3.45 Mil. Brii Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$0.00 Mil. Brii Biosciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$3,411.54 Mil. Brii Biosciences's debt to equity for the quarter that ended in Dec. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Brii Biosciences's Debt-to-Equity or its related term are showing as below:

During the past 5 years, the highest Debt-to-Equity Ratio of Brii Biosciences was 0.01. The lowest was -0.06. And the median was 0.00.

HKSE:02137's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Brii Biosciences Debt-to-Equity Historical Data

The historical data trend for Brii Biosciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brii Biosciences Debt-to-Equity Chart

Brii Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-0.06

-0.02

0.01

Brii Biosciences Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial				0.01	0.01	-	-	-

Competitive Comparison of Brii Biosciences's Debt-to-Equity

For the Biotechnology subindustry, Brii Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Brii Biosciences's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Brii Biosciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Brii Biosciences's Debt-to-Equity falls into.

Brii Biosciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Brii Biosciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.452	+	0)	/	3411.54
	=	0.00

Brii Biosciences's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.452	+	0)	/	3411.54
	=	0.00

Brii Biosciences (HKSE:02137) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Brii Biosciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Brii Biosciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Brii Biosciences (HKSE:02137) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brii Biosciences Ltd (HKSE:02137) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

BRIBF:USA 7SS:Germany

Address

No. 1 North Yongtaizhuang Road, 3rd Floor, Building 7, Zhongguancun Dongsheng, International Science Park, Haidian District, Beijing, CHN, 100192

Website

https://www.briibio.com

Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed towards developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as the CNS diseases, which have public health burdens in China and worldwide. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.

Executives

Hong Zhi	2101 Beneficial owner
Xyxy Holdings Ltd.	2201 Interest of corporation controlled by you
Booming Passion Limited	2101 Beneficial owner
Boyu Capital Fund Iii, L.p.	2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, L.p.	2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, Ltd	2201 Interest of corporation controlled by you
Tong Xiaomeng	2201 Interest of corporation controlled by you
Boyu Group, Llc	2201 Interest of corporation controlled by you
Boyu Capital Group Holdings Ltd	2201 Interest of corporation controlled by you
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Invesco Advisers, Inc.	2102 Investment manager
Ma Yun	2201 Interest of corporation controlled by you
Yunfeng Investment Iii, Ltd.	2201 Interest of corporation controlled by you
Yunfeng Fund Iii, L.p.	2201 Interest of corporation controlled by you
Yf Bright Insight Limited	2101 Beneficial owner

Brii Biosciences (HKSE:02137) Headlines

No Headlines